Medical Research Consultant focusing on Advocacy, Education and Information for Cannabis Reform and Psychedelic Reform. Medical Professional (Retired)
This cohort #study found that the p-tau217 #immunoassay showed similar accuracies to cerebrospinal fluid #biomarkers in identifying abnormal amyloid β (Aβ) and tau pathologies. A 3-range reference for detecting abnormal Aβ pathology was consistent across 3 cohorts; over 8 years, the largest change of p-tau217 was in #individuals positive for both Aβ and tau. Phosphorylated tau (p-tau) is a specific blood #biomarker for #alzheimers disease (#ad ) #pathology , with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for #research and #clinical use has been limited. Expanding #access to this highly accurate AD biomarker is crucial for wider evaluation and #implementation of AD #blood tests. This study found that a commercially available #plasma p-tau217 #immunoassay accurately identified #biological AD, comparable with results using #csf biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the #preclinical stage. https://lnkd.in/eBuF2NS9
